Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Cemtrex, Inc. (CETX) has increased by 284% to $11.79 - Treasure Global Inc. (TGL) has risen by 135% to $59.83 - Top Wealth Group Holding Limited (TWG) is up 95% at $11.73 - Fulcrum Therapeutics, Inc. (FULC) has gained 49% to $13.29 - MetaVia Inc. (MTVA) is up 33% at $10.90 - Kymera Therapeutics, Inc. (KYMR) has increased by 31% to $87.58 - Confluent, Inc. (CFLT) is up 27% at $29.40 - Immix Biopharma, Inc. (IMMX) has risen by 23% to $6.85 - Nurix Therapeutics, Inc. (NRIX) is up 18% at $21.46 - SU Group Holdings Limited (SUGP) has increased by 15% to $6.44 [3] Premarket Losers - SMX (Security Matters) Public Limited Company (SMX) has decreased by 27% to $242.01 - Meihua International Medical Technologies Co., Ltd. (MHUA) is down 27% at $10.20 - Polyrizon Ltd. (PLRZ) has declined by 16% to $10.90 - Fly-E Group, Inc. (FLYE) is down 16% at $6.90 - Sensei Biotherapeutics, Inc. (SNSE) has decreased by 14% to $8.29 - Kentucky First Federal Bancorp (KFFB) is down 10% at $4.00 - Arteris, Inc. (AIP) has declined by 7% to $16.27 - Fusion Fuel Green PLC (HTOO) is down 6% at $3.89 - Kamada Ltd. (KMDA) has decreased by 5% to $6.69 - iOThree Limited (IOTR) is down 5% at $3.11 [4]

KT-621, Oral STAT6 Degrader, Phase 1b Results 1 Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 BroADen Phase 1b Data Jared Gollob, MD Chief Medical Officer Closing Remarks Nello Mainolfi, PhD Founder, President and Chief Executive Officer Question and Answer Session 2 Forward Looking Statements This presentation contains forward-looking statements within the me ...

Core Insights - The biopharma company is focusing on KT-621 as a treatment option for patients suffering from Type 2 inflammatory diseases [1] Company Focus - The company is developing KT-621 specifically targeting Type 2 inflammatory diseases, indicating a strategic emphasis on addressing unmet medical needs in this therapeutic area [1]

Core Insights - Kymera Therapeutics announced positive clinical results from the BroADen Phase 1b trial of KT-621, a first-in-class oral STAT6 degrader for atopic dermatitis (AD), demonstrating significant efficacy and safety [1][2][26] Study Results - KT-621 achieved median STAT6 degradation of 94% in skin and 98% in blood across both 100 mg and 200 mg dose groups, indicating strong translation from healthy volunteers to AD patients [1][7] - Significant reductions in Type 2 inflammatory biomarkers were observed, including a 74% median reduction in TARC for patients with baseline levels comparable to dupilumab studies [1][8] - Clinical endpoints showed robust activity, with a mean EASI reduction of 63% and a mean peak pruritus NRS reduction of 40% across all patients [1][15] Comorbid Conditions - In patients with comorbid asthma, KT-621 achieved a median FeNO reduction of 56%, indicating potential benefits for asthma control [1][21] - Patients with comorbid allergic rhinitis experienced significant improvements in symptom scores, demonstrating KT-621's broader applicability in Type 2 inflammatory diseases [1][22] Safety Profile - KT-621 was well-tolerated with no serious adverse events reported, consistent with findings from the Phase 1a study [4][23] Next Steps - The ongoing BROADEN2 Phase 2b trial in moderate to severe AD patients is expected to report data by mid-2027, while the BREADTH Phase 2b trial in asthma is set to start in Q1 2026 [4][24] Company Overview - Kymera Therapeutics is focused on developing oral small molecule degraders to address immunological diseases, with KT-621 being the first STAT6-directed drug in clinical evaluation [26][27]

Group 1: Market Movements - Several healthcare and biotech companies experienced notable gains in after-hours trading, driven by clinical updates, recent announcements, and technical rebounds [1] - Kymera Therapeutics Inc. (KYMR) saw a 9.58% increase to $73.00 after hours, following a modest 0.59% rise during the regular session [2] - Ocular Therapeutix Inc. (OCUL) advanced 11.29% to $14.00 after hours, with a 1.21% increase during the day [3] - Guardian Pharmacy Services Inc. (GRDN) shares rose 2.62% to $30.54 in after-hours trading, extending its earlier 1.50% gain [4] - Predictive Oncology Inc. (POAI) jumped 13.62% to $4.84 after hours, recovering from a 22% decline during the regular session [5] - Acumen Pharmaceuticals Inc. (ABOS) edged up 3.23% to $1.92 after hours, following a 6.06% drop during the day [6] - EUDA Health Holdings Ltd. (EUDA) rose 7.72% to $2.93 after hours, recovering from a 6.85% decline earlier [7] - Butterfly Network Inc. (BFLY) gained 4.90% to $3.21 after hours, after finishing the regular session flat [8] Group 2: Company-Specific Updates - Kymera Therapeutics is set to announce results from the BroADen Phase 1b clinical trial of KT-621 for atopic dermatitis on December 8, which has fueled after-hours momentum [2] - Ocular Therapeutix recently announced progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, with the first patient randomized on November 24 [3] - Predictive Oncology regained compliance with Nasdaq's minimum stockholders' equity requirement, which has renewed investor confidence [5] - Acumen Pharmaceuticals presented new research at the CTAD conference, highlighting advancements in Alzheimer's treatment [6] - EUDA Health announced a securities purchase agreement for a convertible warrant valued at $100,000, providing financing flexibility for growth initiatives [7]

Core Insights - Kymera Therapeutics, Inc. is set to announce results from the BroADen Phase 1b clinical trial for KT-621, an oral STAT6 degrader for atopic dermatitis, on December 8, 2025 [1] - KT-621 has shown complete STAT6 degradation and a favorable safety profile in early studies, indicating its potential to transform treatment for over 130 million patients with Type 2 inflammatory diseases [3] - Ongoing and planned clinical trials for KT-621 aim to accelerate its development across multiple indications, including asthma and other Type 2 diseases [4] Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation to develop innovative therapies for significant health issues [5] - The company has advanced the first degrader into clinical evaluation for immunological diseases and aims to build a robust pipeline of oral small molecule degraders [5] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces, reflecting its commitment to innovation and employee satisfaction [5]

Company Overview - Kymera Therapeutics reported a third-quarter 2025 loss of $0.90 per share, which was wider than the Zacks Consensus Estimate of a loss of $0.71 per share and compared to a loss of $0.82 per share in the same quarter last year [3] - Collaboration revenues for the quarter totaled $3 million, significantly missing the Zacks Consensus Estimate of $27 million, and were derived from a partnership with Gilead Sciences [4] - Research and development expenses increased by 22.6% year over year to $74.1 million, primarily due to investments in the STAT6 program and growth in the R&D organization [5] Financial Performance - General and administrative expenses rose to $17.3 million from $15.5 million in the previous year, driven by higher legal and professional service fees and increased personnel costs [6] - As of September 30, 2025, Kymera had $978.7 million in cash and equivalents, which is expected to sustain operations into the second half of 2028 [7] Market Reaction and Estimates - Following the earnings release, there has been a 6.52% upward shift in consensus estimates for Kymera Therapeutics [8] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [10][11] Industry Comparison - Kymera Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where Illumina has seen a 4.5% gain over the past month [12] - Illumina reported revenues of $1.08 billion for the last quarter, reflecting a year-over-year increase of 0.4%, with an EPS of $1.34 compared to $1.14 a year ago [12] - Illumina's earnings for the current quarter are projected at $1.22 per share, representing a year-over-year change of 41.9%, and it holds a Zacks Rank of 1 (Strong Buy) [13]

Summary of Kymera Therapeutics FY Conference Call Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Founded**: Nearly 10 years ago, celebrating its 10-year anniversary in May 2026 - **Focus**: Targeted protein degradation, particularly in immunology markets, addressing large unmet needs where targets have been inadequately drugged [3][4] Core Programs and Pipeline - **Current Focus**: The STAT6 program, with significant data expected to be shared soon from a patient study, and ongoing Phase 2 studies [4][6] - **Pipeline**: Five programs in the clinic, including two partnered programs and one wholly owned program, with more expected to be discussed next year [5] STAT6 Program Details - **Phase 1B Study**: Ongoing, providing confirmatory evidence for dose selection for the Phase 2B study [6][7] - **Phase 2B Study**: Recently initiated, focusing on dose range finding with three doses being tested [7][12] - **Objectives**: To confirm translation of pharmacokinetics (PK) and pharmacodynamics (PD) from healthy volunteers to patients, assess clinical outcomes, and evaluate biomarkers [9][12] - **Study Size**: Approximately 20 patients, with a treatment duration of four weeks [10] - **Data Expectations**: Full data set to include safety, biomarkers, and clinical endpoints, with results expected by mid-2027 [30] Safety and Efficacy - **Safety Profile**: Expected to be similar to Dupixent (dupilumab), with potential adverse events like conjunctivitis anticipated [23][24] - **Mechanism of Action**: The drug selectively targets STAT6, blocking the IL-4/IL-13 pathway, which is crucial for its therapeutic effects [23][25] IRF5 Program Overview - **Target**: IRF5, a transcription factor involved in various autoimmune diseases, with a unique approach to drugging this target using a highly potent oral degrader [32][33] - **Clinical Development**: Moving into Phase 1 healthy volunteer studies early next year, with data readouts expected shortly thereafter [34] - **Target Degradation Level**: Aiming for over 90% degradation based on preclinical data, which has shown superior activity in lupus models compared to existing treatments [35] Additional Insights - **Cytokine Challenge**: Unlikely to be included in the Phase 1 study design, focusing instead on ex vivo assessments of pathway activation [39][40] - **Biomarkers**: Main pharmacodynamic markers will include IRF5 itself and activation pathways, with ongoing evaluation of the best assays to use [39] Conclusion Kymera Therapeutics is advancing its innovative approaches in targeted protein degradation, with significant focus on the STAT6 and IRF5 programs. The company is positioned to address unmet medical needs in immunology, with upcoming data expected to provide insights into the efficacy and safety of its therapies.

Company Overview - Kymera Therapeutics is a leader in the targeted protein degradation field, approaching its 10-year anniversary since founding in May [2] - The company has evolved significantly in terms of capabilities and pipeline development [2] Focus Area - Kymera has narrowed its focus to the immunology space, identifying substantial opportunities to develop drugs that leverage targeted protein degradation [3] - The company aims to achieve biologic-like efficacy while maintaining a safety profile comparable to existing biologic drugs [3]

Financial Data and Key Metrics Changes - The company has a cash position of $980 million, providing a runway into the second half of 2028, which will fund both Phase II-B studies and the initiation of Phase III studies for STAT6 and IRF5 programs [29][30]. Business Line Data and Key Metrics Changes - The company is focusing on two wholly owned programs: the STAT6 program, which is nearing data readout, and the IRF5 program, set to enter the clinic next year [3][4]. - The STAT6 program has progressed through Phase I-A and is currently in Phase I-B, with plans to initiate Phase II-B studies for atopic dermatitis and asthma [10][20]. Market Data and Key Metrics Changes - The atopic dermatitis market has over 40 million diagnosed patients, but only about 1 million are treated with Dupilumab, indicating a significant unmet need that the company aims to address with its oral drug [21][22]. - The company sees a large opportunity in the pediatric population for oral medications, which are more accessible than injections [34][35]. Company Strategy and Development Direction - The company plans to focus on the two largest markets, atopic dermatitis and asthma, for its Phase II-B studies, which represent a significant portion of Dupilumab's sales [24][25]. - The company is not currently interested in partnering for the STAT6 program, believing it can execute the studies more effectively on its own [25][27]. - The company aims to introduce one new program per year, with a focus on expanding its pipeline and addressing multiple indications [69]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the competitive landscape but believes that their unique approach to targeted protein degradation positions them well for success [70][72]. - The company is committed to accelerating development timelines and minimizing idle time between clinical phases [45][49]. Other Important Information - The company is exploring the use of AI to enhance clinical operations and improve efficiency in patient recruitment and data analysis [53][54]. - The IRF5 program is positioned to target multiple autoimmune diseases, with strong preclinical data supporting its potential effectiveness [61][62]. Q&A Session Summary Question: How does the company plan to maximize the commercial opportunity for 621? - The company is focusing on the largest markets and considering potential partnerships in the future, but currently aims to maintain control over development [24][25]. Question: What is the company's strategy for accelerating development? - The company plans to conduct two Phase II-B studies that will inform multiple Phase III studies across various indications [45][46]. Question: How does the company view the competitive landscape in targeted protein degradation? - The company believes its focused approach and deep expertise give it a competitive advantage over larger firms with less targeted efforts [70][72].